Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-1723

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection ; volume:13 ; number:1 ; day:13 ; month:10 ; year:2022 ; pages:1 ; date:12.2022
Nature Communications ; 13, Heft 1 (13.10.2022), 1, 12.2022

Classification: Recht

Creator: Khan, Khadija
Karim, Farina
Ganga, Yashica
Bernstein, Mallory
Jule, Zesuliwe
Reedoy, Kajal
Cele, Sandile
Lustig, Gila
Amoako, Daniel
Wolter, Nicole
Samsunder, Natasha
Sivro, Aida
San, James Emmanuel
Giandhari, Jennifer
Tegally, Houriiyah
Pillay, Sureshnee
Naidoo, Yeshnee
Mazibuko, Matilda
Miya, Yoliswa
Ngcobo, Nokuthula
Manickchund, Nithendra
Magula, Nombulelo
Karim, Quarraisha Abdool
Gottberg, Anne von
Abdool Karim, Salim S.
Hanekom, Willem
Gosnell, Bernadett I.
Lessells, Richard J.
Oliveira, Tulio de
Moosa, Mahomed-Yunus S.
Sigal, Alex

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-022-33371-0

URN: urn:nbn:de:101:1-2022123021175434086542

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Khan, Khadija
Karim, Farina
Ganga, Yashica
Bernstein, Mallory
Jule, Zesuliwe
Reedoy, Kajal
Cele, Sandile
Lustig, Gila
Amoako, Daniel
Wolter, Nicole
Samsunder, Natasha
Sivro, Aida
San, James Emmanuel
Giandhari, Jennifer
Tegally, Houriiyah
Pillay, Sureshnee
Naidoo, Yeshnee
Mazibuko, Matilda
Miya, Yoliswa
Ngcobo, Nokuthula
Manickchund, Nithendra
Magula, Nombulelo
Karim, Quarraisha Abdool
Gottberg, Anne von
Abdool Karim, Salim S.
Hanekom, Willem
Gosnell, Bernadett I.
Lessells, Richard J.
Oliveira, Tulio de
Moosa, Mahomed-Yunus S.
Sigal, Alex
SpringerLink (Online service)

Other Objects (12)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Related objects

Reset password